Pharma and healthcare companies to face continued margin pressure: HDFC Securities

The Indian pharma sector is facing pricing pressure and increased competition, making margin sustainability a key concern. Q4 earnings will be crucial for validating these trends.

Maintain a cautious stance on pharma and healthcare stocks; look for shorting opportunities in companies that miss earnings expectations due to margin compression.

For Indian markets, this story mainly matters for the Pharmaceuticals, Healthcare pocket. The current signal is bearish, so traders should watch whether the effect spreads across the sector or stays limited to a single name.

Watch whether the market validates this read through price action, volume, and breadth. If the headline matters, the signal should show up in execution, not just in commentary.

• •HDFC Securities projects moderate revenue growth for the Indian pharmaceutical and healthcare sector in the March quarter.
• •EBITDA margins are expected to remain flat for the sector.
• •The brokerage forecasts sales growth of 11% YoY and EBITDA growth of 6% YoY for its coverage universe.
• •Risk flag: Unexpected positive regulatory developments (e.g., USFDA approvals)
• •Risk flag: Stronger-than-expected domestic demand